Discuss the recent capital raising and news from the company. All participants are in a listen-only mode. There'll be an initial presentation lasting for approximately 20 minutes, followed by Q&A. If you have a question you'd like to submit, please feel free to type it in using the Q&A function within Zoom. Presenting on behalf of Chimeric today, we have the CEO, Dr. Rebecca McQualter. To begin, I'll hand it over to Rebecca. Please go ahead. Thanks, Matt, and thank you, everybody, for joining. You're going to have to bear with me today. I've been battling the flu this week, and I've just got my voice back today, but I'm ready to go. Thank you for bearing with me today. We've been very busy at Chimeric for the last few weeks, and I'm really delighted to be sharing this update with you. I just want to share our disclaimer. I think this is really important because I will be making forward-facing statements, but these are just plans, and there's nothing set in stone here. Just a quick refresher about Chimeric. I know most of you on the line are followers, and you probably know all of this already, but we've got four phase I clinical trials that are open and running across the U.S., and this is a lot of work and a lot of heavy lifting. I’d really like to say thank you to my executive team, Dr. Jason, Dr. Stephanie, and Dr. Agathe, for working really hard to maintain. I think it's really hard to maintain four trials with four people, but here we are, and we're doing a really great job. In the next 12 months, we're going to have a lot of data coming out, which I'm very excited to share, and I think we're really delighted to have the only CAR-T that's under an FDA IND for CDH17 as well. Somebody did point out that on this slide, I've got shares on issue as 1.6 billion, and that's what they are today. When we have the AGM in the middle of July, we'll probably double in size, so that will change shortly, but thank you for catching that for me. We've also designed this presentation today to really answer some of the questions that came in over the last few days since we've announced the webinar. I really wanted to be thoughtful to take into account every question that's come in to make sure that we answer it. Please, as Matt said, please pop a question in the chat if I don't address it. As you know, we've got three amazing assets, but today I'm only going to update you on CDH17 and our CHM CORE-NK program, and we'll have plenty of things to update you on chlorotoxin moving forward. Today's only going to be about our two programs on either end there. All right, let's dive into some great news on the CHM CDH17 trial. As you will recall, CDH17 is expressed on the cancer surface like this, kind of like my picture behind me, which makes it really great for the CARs to engage with that cancer. We've got a phase I II up and running, and now we have four active sites. You would have seen our announcement about Emory coming on board. We have Sarah Cannon, UPenn, U Chicago, and Emory on board, which is great. I think the reason why I say we're rapidly recruiting is because I've got a line out the door of patients, and I just don't have enough money to say yes to everyone. We're kind of moving at the pace that our budget allows us to. I think there's been a few questions about, "Oh, why haven't we done X amount of patients so far?" The answer really is money, and we've got to maintain a business whilst treating patients, which is a really delicate balance to find. I think we found a really good space now, and now that we've completed the raise, which I'll touch on in a minute, it really gives us the space to breathe and be able to do what we can do, which is great. We've dosed four patients, as you're aware. We've had three more patients manufactured for, so that's seven successful manufacturing runs. Now, all of those runs have been paid for, so we're actually in a really good position. This morning, I found out that we have patient eight, nine, and 10 that are going to go into screening, which is great. As soon as we finish Dose Level 2, we'll have the space to move to dose level three if it's deemed safe by the FDA. We're in a really good position to get to that end of dose level three within probably four or five months. Everything going to plan. Don't hold me to that five months because things happen with human trials. I think the hardest thing for me is to say to all of these sites that we can't enroll everybody at once. We just don't have that kind of budget. I'm delighted to have that problem, and we've got so many patients that are really keen to get on board the study. We actually have an Australian patient that will be flying to the U.S to join the study, which is really exciting. We can't wait for them to join, and hopefully, they don't have any issues. Quickly, I wanted to summarize the clinical preliminary results that we have at dose level one. Just to remind you, dose level one is 50 million cells. This is one dose once only. That's it. The end. Patient one, as you know, with colorectal cancer, he's lost to follow-up, and we've had a lot of questions about him, but this is a normal thing in human trials where these are humans, and we cannot force them to do anything that they don't want to do. He missed some key data points that we needed to collect, which is why we had to dose the fourth patient at dose level one. This slows down our progress a little bit, but the FDA said, "No, you need three complete data sets before you can move to Dose Level 2." That's exactly what we did. Patient two had stable disease for five months, and she's just had a minor progression now. It's been a little bit hard to adjudicate her because the tumor looks like it's dead. It's full of necrosis, but the size is a little bit bigger. It was sort of sitting at the 10-centimeter mark. Now, I think it's roughly 10.2 or something a little bit larger. We're going to have to have that adjudicated by a third party, but we've kind of marked it as a minor progression. We don't really know how to interpret it. There's no benchmark in the solid tumor CAR-T space for this kind of result. We really are pioneers in cell therapy with this particular patient and trying to judge what's going on. If I remind you, she had a really nasty, really aggressive cancer. It was the same one that took Steve Jobs' life. For her to have stable disease for five months at one dose of only 50 million cells is amazing. We'll take what we can get for her, which is fantastic. For patient three, she's still in stable disease with colorectal cancer at her latest scan, which is great. The patient four we just recently treated with colorectal cancer, she reported progressive disease on day 28. This is what we anticipated to see at dose level one of 50 million cells. I wanted to give you some context about how small a dose this is. For the commercial CAR-Ts on the market, they do between 500 million-600 million cells per dose, and that is really worked out on a kilogram per multi-million cell basis. We are starting way down at 50 million cells. We actually did not anticipate to see any stable disease, any cell expansion, any of the CARs performing the way that we thought they would. Here we have two cases where we have seen that, which is fantastic. The blood results for patient one that we have up until day 14, we've also seen a little bit of expansion in his CAR-T population, which is what we want to see, but then we've lost the rest of the data set there. I think I'm really happy with where we are. With this data, we were able to get Dose Level 2 clearance from the FDA, which means that we're safe. We haven't seen any off-target effects, which is really important in this context because a lot of the other CAR-Ts in this particular setting with colorectal cancer and neuroendocrine tumors have seen a lot of gastrointestinal side effects. We haven't seen that at all. I think this really highlights how good the target is. I thought it was good when I joined Chimeric, but now we're actually seeing how good it actually is. Okay, what's next? I just wanted to share with you how we're going to move forward for Dose Level 2, but I really want to stress this is an example. Please don't ring me on June 28 asking me where a scan is because we don't know when patient five will be treated. I really want to make that clear. This is a human study. We have human factors. For example, patient four didn't want to be treated until three days after her birthday. We can't say no to that. We can't force them to be treated on their birthdays, for example. There are a lot of different factors that come into the human trials here. We've manufactured doses for patients five, six, and seven. Those products are sitting at the sites in the freezer, ready to rock, which is great. We're commencing the dose of 150 million cells, which again is still relatively low to the commercial CAR-Ts, but this is the way that the FDA would like us to proceed. We have to monitor safety in patient five for 28 days. That's the dose-limiting toxicity period, and you'll hear me say DLT period. This is a time where we need to see what the CARs are doing, how they expand, if they expand too much, and however they perform. I'll be really interested to see. Between patient six and seven, we only have to wait seven days if it's deemed safe for patient five. If that's not the case and we don't deem it safe, then it's 28 days in between patients. It's kind of we can't really make that assessment until we finish the 28 days with patient five about where we'll be. Again, there's a lot of variability here with these CAR-T trials. As an example only, and I'm stressing this is an example, if patient five gets treated on June 1st with Dose Level 2, their DLT period will end on June 28. They'll have a 28-day scan as well on June 28. We will go to the FDA just to say, "Hey, this is what's happening," and then we should be okay to dose patient six in the week following. We also have to make sure that patient six is ready to go, there's no issues, and that we can do it more straightforward. Over the next few months, we'll have these three patients' data coming in. Okay. Now I'm going to move to the next update. Hopefully, I've answered a lot of the questions about where's all the patient data, how many patients have been manufactured for, and hopefully, I've made that really clear before I move on to CHM CORE-NK. Okay. This is really exciting. As you guys are aware, this is an off-the-shelf product that we have two trials running. I'll update you on one of the trials today, which is the one ADVENT- AML running at MD Anderson. The other trial happening at Case Western is moving quite slowly, but because this is not a, they are both investigator-initiated trials, and they are paying for the bulk of the trials, we do not have much say unless I start throwing money at them, which we do not really have any spare money to influence the trial. We can do our best, and I always meet with them when I go over to make sure that they are tracking well. I think one of the things that has happened recently is that the new administration in the U.S. has removed all of the university funding. We find MD Anderson, Case Western, Penn, they are really trying to find their feet with their funding now because that has all been removed. We've got to give them a bit of space so that they can figure out how to fill the gaps that have been taken away now, which is really unfortunate. I think we rely so heavily as Aussie biotech on these assets coming out of these universities. It's just really slowed it down, which is disappointing, but again, something that's out of our control. With our allogeneic NK product, we can make 200 doses from one healthy donor, and that costs around AUD 200,000, which is really cost-efficient. We're really grateful for our partners at MD Anderson and Case Western for using our NK cells. We reported, I think it was in November, that we had the cohort one for the MD Anderson ADVENT- AML study, and these were in relapsed- refractory patients. This was just a safety observation for dose expansion. We did not see any safety issues, and we were clear to move to cohort two, which is 20 patients frontline. This is a first in cell therapy. Most of the time in cell therapy, they are given fourth- line or fifth- line. They have had multiple doses of chemo, then they are given these cells. The question that MD Anderson were really keen to answer, and our lead investigator, Professor Abhi Maiti, who is fantastic, he wanted to see if we give the cells first up, what happens? We are not aware of any other company doing this, and I think it is really exciting to be in this space. Let me just remind you really quickly of the protocol. We have got the cells first, and these are just vanilla cells. They are not engineered, but they are very happy, and they look really great going into the patients. It is followed by standard of care, which are two FDA-registered chemotherapy drugs. As you saw, the great news on Thursday last week, we got the results at 6:00 A.M. when I was on a call with them on Thursday morning, and we got it out to the market as soon as we could. It is kind of random how many updates I get from MD Anderson. Like I said, it is an investigator-initiated trial, and so they are not obliged to tell us anything. I am just really lucky we have a great relationship with them and the AML center there. To reiterate the results, we had two patients that achieved a CRi, so that is a complete response with an incomplete blood count recovery. This is normal in an AML patient where their platelets might be a little bit low or their neutrophils might be a little bit low, and their marrow is just having some time catching up to bouncing back to the normal blood count levels, but there is no evidence of leukemia in the blood or in the marrow, which is really exciting. These patients are older patients that are not eligible for any other treatment. Typically for these patients, we would only expect a 1/3 of them to respond. Here we have seen 2/3 of them respond, so 66%. The proof will really be in how long we can keep them in a complete response state and how active the NK cells are. This is what we call a durability of response. From the first cohort that we did last year, we can see that the cells are active for around 60 days, between 60 and 90 days. We are really hoping to keep these patients in a complete response for that long, but AML is pretty tricky. I am really keen to see how we go. They dosed patient four last week and patient five this week. We are kind of getting a bit of momentum here. Hopefully, I will get a few more updates from them. Like I said, it is an investigator-initiated trial. I am going to stop there on my presentation now. I just really wanted to take this opportunity to give you a business operations update, if that is okay with everybody, because we have had so much data coming out. Let me just finish my slideshow here. We've had so much data coming out that I think it's really important for me to give you a bit more of a business operations update. Firstly, I just wanted to touch on the capital raise and our financial position. I think since I joined, we haven't really had any money in the bank. Today, I'm very proud to sit here and tell you that we've got a bit of money in the bank. It's not much, but we'll take it. We received the $4 million non-dilution refunding from one of my friends now in the U.S. from a U.S. family office. What was really interesting is that they found us. They're a very fancy medical team, which are full of Harvard doctors, really like CDH17. They're really focused on finding a cure for colon cancer and also supporting female CEOs, which is why we were given that non-dilution refunding to ensure that we can continue the trial and manufacture CDH17 doses. I'm very lucky for those supporters that we have there. I also want to say thank you to our very loyal shareholders who generously contributed $1 million via a rights issue. I know that you've been through a lot, and you've been through the highs of the IPO price and then down through where we are right now. I think it really means a lot to me that you want to support us in what we're doing with that $1 million via the rights issue. However, we do have a shortfall of about AUD 2.2 million that we still need to place. When we got the news on Thursday morning, we had so much demand to put together a capital raise that the wholesale institutional investors kind of said, "Hey, this is what we've got to offer. Will you take it?" Now, for a company like us that does not have much money, we are not in a position to say no. We raised AUD 6.6 million. The book actually went to AUD 7 million. I really want to say thank you to Sean Kennedy at Pack Partners and Taylor Collison for their support for the raise. I think what was really exciting is the U.S. family office that supported us with the non-dilution grant also became the cornerstone with $1 million in that AUD 6.6 million, which is really exciting. I am really grateful now that we are in a pretty good financial position. Now, this doesn't mean that I'm going to go spending money like crazy. We still need to have the appropriate budget constraints in place. I don't want to suddenly put 10 people on the trial and be in a position where we have no money again. I think spending time with my CFO, who I really like to say thank you to as well, we've spent a lot of time reducing all of the costs. I wanted to speak a little about operational costs. Since I joined over a year ago, we've really spent a lot of time focusing on what do we actually need as a business, and we actually need data. All of the money is going towards data. I'm not paying $2,000 a month for a fancy investor website. I'm not paying $3,000 a month for a video every three months. I can do that here with my setup. For example, I do all the slide decks. If you find any mistakes, it's me. I don't pay anyone else to do it. We're really focused. My team do exactly the same thing. They're doing all of the forms. They're not outsourcing anything. I think we have two consultants that we need for batch release for the doses, and that's it. We don't have anybody else. It's taken about a year to get to a place that I'm really happy with and running this budget like it's my own household budget because we've got patients that want to come onto the trial. If I'm spending money here, there, and everywhere, we're not going to be able to treat patients. I think in FY23 and FY24, there are actually 14 full-time employees of Chimeric Therapeutics. Now, this was long before my time. Last year, we had seven. Now we have four. We are a very small team. There's me here in Melbourne and then three in the U.S.. My Chief Medical Officer, Dr. Jason, my Chief Scientific Officer, Dr. Stephanie, and my Head of Manufacturing, Dr. Agathe, all in the U.S.. We are all cell therapy experts. We've all worked in this industry for a very long time. I think when you have a small group of experts, it's not easy. It's easier to achieve the same result because we know what we're looking for. We know when something doesn't look right, and we can challenge the cost as well. I want to really thank my Head of Manufacturing. She's done such a great job at watching those manufacturing costs, keeping them down, making sure that every batch we are down to the milliliter of reagents that we use. I'm very, very grateful for her keen eye on this. You would have seen last week or the week before, I went to our manufacturing facility to meet the new owners. They're a big American VC company called Altaris. I got to meet the new leadership team. I got to meet the new leadership team on site of the manufacturing facility, which changed from a Chinese parent to an American parent. It's really important to have a good relationship with our manufacturing facility because manufacturing is the key for cell therapy. I think you hear me say all the time, we've had seven successful manufacturing runs. That's so important for the success of our program. A really big thank you to Dr. Agathe for that. Most of our costs now really are funneled into the CDH17 program, and that's around 60% if I get my maths right. 10% funds the CORE-K trial. We have some milestone payments for that, and we have the manufacturing associated with that. The rest, around 30%, are all corporate costs. Corporate governance, our accounting, and all of those types of things, and payroll as well. We've really spent a lot of time reducing the payroll burden. I'd also like to say thank you to the board who haven't taken payment for quite some time. I'm really appreciative of them helping us out with the budget constraints. Finally, I just want to touch on shareholder communications. I think this year we've had 42 ASX announcements. I don't know if you've ever dealt with the ASX, but they need to approve every release that goes out. Sometimes they will say, "No, this is not an ASX release. Please put it on social media." I think the example that came up is the CDH17 results that we announced on social media. We did that because we were directed by the ASX to do so because they felt that it was not market-sensitive, which I'm not going to comment on why they made that decision, but that was the decision that was made, and that's why we had to do it that way. Definitely not my preference. I think any clinical trial results are material, but that's what we had to deal with. From time to time, you may see that, and that's usually the case of why that's happened. I think we're really motivated to share everything with our shareholders as soon as we know. For me, corporate governance is really important. We've got a really fantastic co-sec who is a corporate governance wizard, Nathan. I'm very grateful for his support throughout these negotiations with the ASX, which have become quite tricky. My final point I'd like to make, and I've gone a little bit over time before we get into questions, is really just around the forecast timelines. We've had a few comments from people saying, "Hey, you should have delivered this many patients, X, Y, and Z." I think we plan for success, but that's not always the case, right? When we have human clinical trials, we've got multiple variables. I really wanted to highlight those variables for you today so you can really understand, for me, making a decision about whether we let the next patient on the trial or not. Firstly, it's money, right? Let's park the money. We've had a discussion about money. I've got a little bit of money in the bank now. The second thing is the FDA. Now, with the new administration, half of the FDA staff have now been moved to the Department of Immigration. I'm very lucky that we've got a very strong relationship with the cell and gene therapy group at the FDA that we can still have quicker negotiations. Some of the processes have blown out from a three-day process that's now a 60-day process or a 30-day process. Because of the changes, and they've completely wiped out the bottom of the FDA, all the junior project managers that were really important to getting behind-the-scenes work done, it's getting really hard to work with the FDA. I think we're really lucky because we have that relationship, and my CMO has got very strong relationships there. I'm very, very happy with how we're moving, but we've still noticed that things have slowed down. For us, it's days, but even to get the Dose Level 2 clearance took longer than we anticipated. That's completely out of our control. I can't really influence how Mr. Trump runs the FDA. The other thing, I've got a long list of variables to go through here, so you're going to bear with me. We've got the clinical trial sites. Things happen at the clinical trial sites all the time. These are big major hospitals, and there's patients that are far more sicker that need to be treated first, and then we can deal with our trial screening, et cetera. We also have various regulatory requirements. For example, even though our process to manufacture is only nine days, we have a seven-day regulatory requirement of batch release, and that's an interim batch release. We do a three-month batch release, which is a lot longer, but we can treat the patient in between there. All of those different things are subject to change as well. If there's a question on one of the releases, then we've got to go back and address that question. It's not really a straightforward process like manufacturing paracetamol because we're manufacturing human cells and it's human tissue. There's going to be variability in each batch, and we need to keep it in a tight window. For the seven successful manufacturing runs, my Head of Manufacturing has done a very, very, very successful job at keeping it in the tight window. We haven't had too many regulatory comments. We also have a safety monitoring committee that meets once a month, and this is really important in a cell therapy first-in-human trial. If the safety monitoring committee have any questions, then we need to address those before we can move forward. For example, in patient two, we saw the cytokine release syndrome, which we expect when we give a CAR-T, and they just wanted to make sure that everything was as it was, and then we move forward. That adds a week on here, a week on there. I think I mentioned about patients not wanting to be treated around special occasions. We were ready to treat a patient just before Christmas, and they said, "No, can we be treated in the first week of January?" We are not going to say no to something like that, and we cannot force humans to do what we want them to do. This is kind of really tough because I know most of our shareholders play in the mining sector as well. You are digging a mine, and you put the machine there and you dig it. It is kind of binary. I think there is a lot of gray area with human interaction here in the trial. I just really wanted to highlight that for you today. The other thing to note is if we have expected dose-limiting toxicities, if we have unexpected findings, we have to wait, and we have to process those results before we can move forward. We really want to do that because we want the best outcome for the patients and the company. If we move forward too fast and we do not make sure we tick all the safety boxes, not only is it going to hurt a patient, it is going to hurt the business as well. I would say that we are optimistically cautious as we move through the first-in-human part of the trial. The other thing I wanted to share is our manufacturing facility has two mandatory FDA shutdowns a year. That means there are two months we cannot manufacture in a year. We cannot do 12 patients in a year. I mean, we can't afford to. Just to note that these are all the variabilities, again, that we are taking into account when we're deciding, "Okay, do we move ahead now or do we wait?" Finally, these are humans. I'm sure that lots of different humans in your life, and everybody has a different priority and a different lens. We can't really have another one go missing, which has been really good for the sites to make sure that we pick the right patients now moving forward. These are humans, and we kind of can't have a binary approach or a black-and-white approach to them. We need to have a little bit of gray. All of our principal investigators are really good at that at our four sites. I really hope all of my comments today have answered a lot of your questions. If not, let's go to questions, Matt. My voice has held up. I'm very impressed. That's well done. Thanks, Rebecca. As you said, we'll move on to the Q&A, and I've just got a little bit of time left. As mentioned earlier, if you want to send a question in, use the Q&A function within Zoom, but I'll jump straight into them. First question is, did the latest results show conclusively that NK cells were a factor? Yes and no. I think for the NK cells and that particular population, for standard of care, we generally see, like I said, a 1/3 of patients respond, and we've seen 2/3 of patients respond in this small little group. It is a small group. Let's remember that. As I mentioned, we really want to be able to see the durability of response. I think time will tell how long they stay in this remission state. We are looking forward to that. If it is the NKs, we will know in about 90 days' time. Do not hold me to that, though. Thank you. The next question I have is, are you engaging with potential partners and Big Pharma, and when do those discussions generally happen? They can happen any time. I think because of the target that we have with the CDH17 program, a lot of eyes have been on us, particularly seeing the unexpected results at 50 million cells. We are always open to those discussions. For us, as we get closer to phase II, it is really important to recognize that we will need a strategic partner to pay for that. I will make sure that I work my hardest to get a strategic partner to pay for that. The discussions are ongoing. Thank you. There has been a lot of noise around the FDA and how Trump has involved himself there. I think you might have touched on it briefly, but is that an issue for Chimeric in any way? Yeah. We are a little bit protected because we are in the cell therapy kind of group, and that is a little small kind of group, also full of cell therapy experts. I think what has really happened is if you go to file an IND now, it is not going to be a 60-day, 90-day kind of thing. It is going to blow out to 120 days for you to get your review. It has been quite significant on some of the big boys like Pfizer, AstraZeneca, and Amgen, for example. Speaking to my friends at Amgen, they have all started to mount a bit of a fight, but they are doing it very carefully. They are announcing, "Oh, we are doing more manufacturing, so you better fix the FDA kind of deal." It is a bit strategic what they are doing. It has impacted us, but I think it has only been a few days that have been impacted for us, not weeks or months yet. Hopefully, it improves if Pfizer are involved. I will let them take the fight for us. Thank you. Just a follow-up on the potential partnering. Would it be different targets for the different assets? Sorry, what was that, Matt? Different targets for? For the different assets, for the different assets in Chimeric. I think we'll take a discussion when it's on the table, and we'll have a look at it. It may be different targets for different assets, or it may be all in one. Anything's an option, but I just really need a partner to pay for phase II. The next question is, what are you looking forward to seeing when it comes to Dose Level 2? We're really excited about Dose Level 2. When I was doing my due diligence on the company, I was excited about Dose Level 2 because it's close enough to the commercial doses to see something, and it's not far away from the safe dose. Now that we're actually here, and I've always thought we're going to see something at Dose Level 2, and that's why I'm excited, my best guesstimate being a cell therapy expert. We can't wait. We know the cells can perform the way we want them to. When they actually attack the tumor, they kind of swarm around the tumor. When I was in Philadelphia and I met with our inventor, he showed me this really cool video of them swarming around the tumor. I think if we have 150 million swarming, we're going to be able to do a really good job of killing the tumor. I'm excited to see that. Can't wait. Excellent. In terms of other activity in the space, is the CAR-T sector still garnering a lot of interest? Yeah. Interestingly, a lot of people are saying, "Oh, no, CAR-Ts are over, blah, blah, whatever." I mean, I'm a bit biased because this is my whole career, but I think there's something there. We're seeing Emily Whitehead, who was the first person to have CAR-T. She's alive today, and she goes to UPenn as a uni student because she had one dose of [CAR-T]. That's it. She hasn't had any more treatment. That's it. She's only had one dose. For her, the investment of $750,000 or whatever it was for her, probably a lot more back then, is worth it, right? We see that case. We really need to figure out how we can replicate that in every single patient. I think we're learning a lot now about in what patients it works in and what patients it won't work in. I think also the product that you put through manufacturing, is it going to be a decent product, or is it going to come out awful? If you've had five lines of chemotherapy, your cells probably aren't going to perform well as if you've had none. There's a few things that we're learning now. I think meeting with the Altaris leadership team, they're really focused on reducing the cost of goods for cell therapy to make it more achievable throughout the whole healthcare system. We really want to help them do that. They've got a lot of big plans, and yeah, we're excited to see where it goes. I think there's a big future for cell therapy. I think now, particularly for solid tumors, we've kind of worked it out for blood cancer. There's still a lot of work to do, but there's six or seven registered products now for blood cancer. It's time for solid tumors, which is great. Thank you. The next question is, do you have any form of status update on the patient who had a complete response in the Case Western trial? Haven't had a status update from that patient, no, but I'm really keen to hear. Next week, I'll be meeting with the PI in Chicago. Hopefully, I'll get an update on that patient. It's pretty hard, like I said, with the universities losing all their funding. They're scrambling and focused on other things. I hope she's doing well. Great. Thanks, Rebecca. I know your voice is just hanging in there, but I'll give it back to you just to provide a closing comment. I just want to say thank you to everyone for your support. I want to say thank you to all of you who've emailed me and supporting us and generously giving us your hard-earned money. Trust me, I treat it like my own when we spend it. We are in a great financial position. I know a lot of people were not happy with the raise in the price, but at the end of the day, we really needed to fund the business. I do not know what would have happened if we did not fund the business. I do not really want to speculate, but we really needed to fund the business. Now we can take a breath. We have got some money in the bank, and we are in a really good position just to deliver results. I am really excited to be able to focus on delivering results instead of trying to find money here, there, and everywhere. I am also really focused on our patients and how we can treat some more patients. I just want to say thank you to the board for their support and for my amazing team of three in the U.S.. They've actually worked quite tirelessly to make all of this happen, and they're really going above and beyond, like having my Chief Medical Officer fill in little forms. All three of them are doing such a great job. I just really want to say thank you for your support, and I really look forward to sharing the next update with you. Thanks, Rebecca, and thanks again to everyone for joining today. We'll look forward to bringing you more through.